UT-WYSS-CENTER
11.8.2020 10:02:28 CEST | Business Wire | Press release
The Wyss Center for Bio and Neuroengineering has granted a worldwide license to Blackrock Microsystems to commercialize its neural signal processing and decoding software platform for research and clinical applications. The agreement follows a long-standing collaborative relationship and represents the first of many important neurotechnology developments the Wyss Center and Blackrock Microsystems intend to advance together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005373/en/
“One limitation of neural signal processing applications is that there is no single software platform that directly works with the multiple devices collecting brain signals. Researchers and clinicians have to develop their own software to analyze the signals from a patient, which limits effectiveness and slows down the implementation of solutions to the clinic,” said David Ibanez, Ph.D., Brain Machine Interface Scientist at the Wyss Center. Ibanez has been leading the Wyss Center’s software platform development efforts over recent months.
Optimized for use with implantable, high-channel count brain-computer interfaces (BCIs), the Wyss Center’s high-performance data analysis platform, called NeuroKey, is an important building block for complete real-time neural interface research and clinical applications, including restoration of movement, communication and control of assistive devices.
The medical-grade platform is compatible with commercial hardware and sensors and can be adapted to custom-made devices. NeuroKey has the potential to accelerate BCI technology research and development for clinical deployment in the lab and at home.
“Access to enabling devices at home, would give me greater independence and freedom,” said Ian Burkhart. Known as a BCI Pioneer, Ian has an enabling neural interface developed by Blackrock Microsystems. He sustained a spinal cord injury during a diving accident in 2010. "Currently BCI devices can only be used under extreme supervision in controlled environments, however, this innovation from Blackrock Microsystems and the Wyss Center pushes research to a stage where these devices can advance into the real world.”
The partnership between the Wyss Center and Blackrock Microsystems is a strong example of the Center’s translational approach. It combines the technical talent and research and development efforts of the Center’s staff with the clinical and market knowledge of Blackrock Microsystems, who has been the leading provider of reliable invasive brain computer interface technology to researchers and BCI Pioneers (tetraplegic patients) for more than a decade.
“Blackrock Microsystems is proud to be collaborating with the Wyss Center in an effort to bring life-changing innovation and neuro technology to patients,” said Marcus Gerhardt, MPhil, MA, Blackrock Microsystem’s co-founder and CEO.
“We hope that this is the first of many joint neurotechnology developments with Blackrock Microsystems, that will have a big impact on many people’s lives,” added Wyss Center’s CEO Mary Tolikas, Ph.D., MBA.
ENDS
About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland
The Wyss Center is an independent, non-profit research and development organization that advances our understanding of the brain to realize therapies and improve lives.
The Wyss Center staff, together with the Center’s academic and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroradiology and neurotechnology, to reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease and to accelerate the development of devices and therapies for unmet medical needs.
The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.
About Blackrock Microsystems LLC
Blackrock Microsystems, based in Salt Lake City, Utah, was founded in 2008 and is the world’s leading provider of technology in the neuroscience, neural engineering, and neural prosthetics space. The company’s technology is at the core of worldwide innovations in Brain-Machine Interfaces (BMI/BCI), implantable bionic technologies and epilepsy diagnostics. Most impactful implantations of the Utah Array have been in some tetraplegic individuals from University of Pittsburgh’s Nathan Copeland, who controlled a prosthetic arm to fist bump US President Barack Obama in 2016; Ohio State University’s Ian Burkhart who is learning to control an automobile, and CalTech’s Nancy Smith who is learning to play a virtual piano. Seemingly easy tasks, all have used the Utah Array to translate their thoughts into action to restore function.
Image
Download
(20 MB)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005373/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio
Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 12:00:00 CEST | Press release
Powered by the Company’s breakthrough L4 and L4 Max Ouster SiliconFeatures the first patented native color lidar sensors with point for point 3D color visionIntroduces flagship OS1 Max sensor with double the range and resolution of Rev7Auto-grade, cybersecure, and designed for functional-safety Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
